Highlights {#Sec1}
==========

Description of thromboelastometry profile of patients with COVID 19.Discussion of the correlation between the thromboelastometry profile and standard laboratory coagulation test results, and the possible pathophysiological hypothesis behind it.Bottom line for management strategies in patients with COVID 19.

Background {#Sec2}
==========

Coagulopathy associated with COVID 19 has been related to significant mortality. Coagulopathy observed in severe illness has been linked with high mortality, and patients who died developed disseminated intravascular coagulation (DIC) and it has been hypothesized, based on coagulation laboratory tests \[[@CR1]\]. Although hyperfibrinolysis is associated with a doubling of mortality in septic critically-ill patients, fibrinolysis shutdown, an acute impairment of fibrinolysis, has also been recognized as a risk factor for increased mortality in these patients \[[@CR2], [@CR3]\].

Both hyperfibrinolysis and fibrinolysis shutdown can be assessed by thromboelastometry, a viscoelastic test that has been used as point-of-care for bleeding risk and hemostatic therapy guidance in critically-ill patients. Furthermore, its potential role in predicting mortality in septic critically-ill patients has recently been reported \[[@CR4], [@CR5]\].

Our aim was to describe the COVID-19 thromboelastometry profile using ROTEM sigma and compare it with standard laboratory findings in critically-ill patients from a Spanish tertiary hospital.

Methods {#Sec3}
=======

Adult patients diagnosed with COVID19 admitted to the intensive care unit (ICU) of the Hospital Clinic of Barcelona between April 5 and April 16, 2020 were prospectively enrolled. The study was approved by the Ethics Committee (HCB/2020/0371). In all cases, consent was obtained by phone from the patient or one relative and in the presence of an independent witness not related to the study. A document with the information of the patient, relative and witness was made and kept for every patient. Patients on anticoagulant treatment were excluded. Thromboprophylaxis was given according to the local protocol (enoxaparin 40--60 mg/day).

Blood citrated samples were obtained specifically for the study from 19 patients in vacutainer tubes (0.129 M) from an arterial line or central or peripheral venous catheter. The laboratory standard coagulation test and thromboelastometry were performed simultaneously within the first hour after extraction and 24--48 h after ICU admission.

Demographics were recorded. Organ failure was assessed using sequential organ failure assessment (SOFA) and disseminated intravascular coagulation scores (DIC and SIC score) were calculated at blood sampling \[[@CR6], [@CR7]\]. Data on hemorrhagic or thrombotic events and transfusion were collected throughout hospitalization for later assessment \[[@CR8]\].

Thromboelastometry was performed with a point-of-care ROTEM sigma device (TEM International, Munich, Germany). Intrinsic coagulation pathway (INTEM) and extrinsic coagulation pathway (EXTEM) and fibrinogen function (FIBTEM) were assessed. Lysis at 30 and at 60 min (Ly60, Ly30) indicated the percentage reduction from maximum clotting firmness (MCF) at 30 or 60 min, and was used to evaluate clot lysis, as previously described \[[@CR9]\].

Statistical analysis {#Sec4}
--------------------

The results are presented as median and interquartile range for continuous variables and percentages for categorical variables. The SIC score was expressed as mean and standard deviation (SD). The Mann Whitney and Chi square tests were used for comparison, as needed. All analyses were performed using the Statistical Package for Social Sciences version 22.0 (SPSS, Chicago, IL), and two-tailed levels of significance were established at 5%.

Results and discussion {#Sec5}
======================

Nineteen ICU patients were included. Baseline patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. Sixty-one percent were male, the median age was 60 years, and the BMI was above the normal range in 80%. The most frequent comorbidity was hypertension (47%). The median SOFA score was 4 \[[@CR2]--[@CR6]\] mainly due to respiratory failure. Thromboprophylaxis with enoxaparin was regularly administered to all patients except one patient who had chronic liver disease and died two days after admission due to acute respiratory failure.

Table 1Patient characteristics, n = 19Age, years61 (55--73)Sex, male10 (53%)BMI, kg/m^2^ (18.5--25)28 (27--32)BMI \> 2515 (80%)Chronic disease, n (%) Hypertension10 (47) Diabetes mellitus4 (19) Chronic obstructive pulmonary disease2 (10) Chronic renal disease2 (10) Chronic vascular disease3 (15) Cancer0SOFA score4 (2--6)DIC score1 (0--3)SIC score1.8 (0.9)Enoxaparin (daily doses), mg60 (40--80)Hemoglobin, g/L (130--170)120 (110--140)Leukocytes, × 10^9^/L (4.00--11.00)9240 (5860--13500)Creatinine, mg/dL (0.30-1,30)0.9 (0.7-2.0)Coagulation laboratory tests Prothrombin time, s (9.9--13.6)12.7 (12.2--13.3) Activated thromboplastin time, s (23.5--32.5)30 (26--31) Platelets, × 10^9^/L (130--400)236 (136--364) Fibrinogen, g/L (1.5--4.5)6.2 (4.8--7.6) D dimer, ng/mL (\< 500)1000 (600--4200)ROTEM (in parentheses, normal range) CT EXTEM (38--79), s78 (63--91) CFT EXTEM (34--150), s41 (40--53) MCF EXTEM (50--72), mm74 (71--76) CT INTEM (100--240), s173 (163--201) CFT INTEM (30--110), s51 (44--64) MCF INTEM (50--72), mm70 (67--73) FIBTEM MCF (9--25), mm30 (24--34) LY30 EXTEM (\> 95%)100 (100--100) LY60 EXTEM (\> 85%)99 (97--100) LY30 FIBTEM (\> 95%)100 (100--100) LY 60 FIBTEM (\> 85%)100 (100--100)The results are presented as median (interquartile range) for continuous variables and percentages for categorical variables. *SOFA* sequential organ failure assessment, *DIC score* disseminated intravascular coagulation, *SIC score* sepsis induced coagulopathy, *BMI* body mass index. The SIC score was expressed as mean and SD. *CT* clotting time, *CFT* clotting formation time, *MCF* maximum clot firmness, *LY30* lysis at 30 min, *LY60* lysis at 60 min, *EXTEM* extrinsic coagulation pathway, *INTEM* intrinsic coagulation pathway, *FIBTEM* fibrinogen function

At admission, high levels of fibrinogen and D dimer were observed, with median values of 6.2 (4.8--7.6) g/L and 1000 (600--4200) ng/mL, respectively. Platelet count was preserved in most patients: mean 236 (136--364 10^9^/L) (Table [1](#Tab1){ref-type="table"}). Thromboelastometry data showed clot firmness in the EXTEM and FIBTEM tests above the normal range, pointing to activation of coagulation. Concomitantly, clot lysis was decreased compared with reported levels in healthy controls \[[@CR5], [@CR10]\]. There were no differences in thromboelastometry parameters, nor in D dimer levels between patients below/above the median SOFA value. A lower platelet count was seen in patients with SOFA \> 4. Patients were followed for 60 days. Two months after study initiation, 4 patients had died and 3 remained hospitalized. The cause of death was respiratory complications in 2 patients and multiorgan failure in 2. There were no deaths attributed to evident thrombotic complications or bleeding. Two patients had bleeding: one required transfusion of 2 units of red blood cells. Five patients had thrombotic complications (2 deep vein thrombosis, 2 pulmonary embolism and 1 myocardial ischemia) and two patients had both bleeding and thrombotic complications. All patients who died and 4 out of 5 patients who had thrombotic events showed Ly60 100% in the EXTEM and FIBTEM tests.

To determine whether the thromboelastometry pattern was stable or changes in a short period of time we repeated it in 5 randomly-chosen patients one week after the first sampling. No significant differences were observed between the two time points (Mann-Whitney U test for paired samples).

Patients with COVID19 showed a hypercoagulable state with a thromboelastometry pattern mainly characterized by decreased fibrinolytic capacity together with a paradoxical increase in D dimer levels, typically seen in hyperfibrinolysis. The decreased fibrinolytic capacity (fibrinolysis shutdown), defined as LY30 EXTEM 100 (100--100)% and LY60 EXTEM 99 (97--100) observed has consistently been reported in septic and non-septic patients with early DIC. Fuat et al. reported that the fibrinolytic system function is markedly inhibited in severe sepsis and is associated with organ disfunction \[[@CR11], [@CR12]\].

Conversely, Panigada et al. \[[@CR13]\], performing thromboelastography (TEG) in intubated patients with COVID19 found normal fibrinolytic capacity with values very close to the limit of hyperfibrinolysis. Additionally, although several criteria have been used to define the hypercoagulable profile in ROTEM/TEG devices \[[@CR14], [@CR15]\], Panigada et al described hypercoagulability in parameters of clot firmness and clot formation in TEG, whereas only one criteria of hypercoagulability (increased clot firmness in both the EXTEM and FIBTEM tests) was seen in our patients on ROTEM. These discrepancies could suggest that ROTEM and TEG perform differently in assessing fibrinolytic capacity in patients with sepsis. Disease severity (not reported by Panigada et al) and the time from disease onset could account for these differences. More recently, Wright et al. \[[@CR16]\] also identified fibrinolysis shutdown using TEG in patients with severe COVID-19, and the presence of the fibrinolysis shutdown in addition to high D dimer levels correlated with thromboembolic events.

However, although high levels of D dimers were found in our patients, they did not meet the criteria for DIC as traditionally defined. Prothrombin time, fibrinogen and platelet levels were not reduced, and this was reflected by low DIC and SIC scores at ICU admission: 1 (0--3) and 1.8 (0.9), respectively (Table [1](#Tab1){ref-type="table"}).

Fibrinolysis shutdown has been defined as fibrinolysis cessation subsequent to initial fibrinolysis activation. This condition has been assessed by viscoelastic global tests \[[@CR17]\] and has been widely evaluated in trauma patients. However, the explanation remains unclear. Some investigators have suggested that a high D-dimer with low fibrinolysis reflects ongoing fibrinolysis not measured by viscoelastic tests and have called this fibrinolytic shutdown "occult hyperfibrinolysis" \[[@CR18]\]. Others have stated that, since D-dimers have a half-life of more than 12 h, they are biomarkers of fibrinolysis activation at some point, but do not reflect current fibrinolytic activity \[[@CR19]\]. None of these hypotheses completely explains our results. Firstly, despite the limited sensitivity for fibrinolytic activity quantification, thromboelastometry represents a convenient method for clot lysis assessment \[[@CR20], [@CR21]\]. Secondly, the prolonged D dimer half-life cannot not explain the growing and sustained levels of D dimer seen in Covid-19 patients, and most probably suggests maintained fibrinolysis.

We propose a different hypothesis to explain high D dimer levels in COVID-19 patients with the global viscoelastic test showing a hypofibrinolytic pattern. The hallmark of the acute lung injury seen in severe COVID19 infection is intra-alveolar fibrin deposition. The proposed mechanism of lung damage is dramatic alveolar-endothelial disruption leading to progressive endothelial pulmonary syndrome with microvascular thrombosis \[[@CR13]\]. It is known that urokinase is produced by lung epithelial alveolar cells and, in a SARS-Cov infected mice model, urokinase increased dose-dependently to the amount of recombinant mouse-adapted SARS-Cov injected \[[@CR22]\]. The parameters of hypofibrinolysis found by thromboelastometry in COVID-19 patients, together with the high D-dimer levels observed may suggest the idea that the lungs could potentially be the main source of D dimers and coexist with a systemic hypofibrinolytic state. Lung-generated D dimers could be due to the fibrinolysis acting on intra-alveolar fibrin membranes or local microthrombi. The fibrinolysis activator in the infected lungs could be the urokinase released by damaged epithelial alveolar cells and endothelium. Therefore, both locally activated coagulation (forming polymerized fibrin) and fibrinolysis (removing the fibrin formed) would partially explain the coexistence of severe hypoxemia together with a relatively well-preserved function of the other organs. In the lungs of patients with severe COVID19, a local imbalance between increased fibrin formation and insufficiently increased fibrinolytic activity in relation to the high burden of fibrin formed could mean that fibrin cannot be properly removed, leading to clinical respiratory manifestations. This concept may open the window to therapeutic options. Wang et al. \[[@CR14]\] reported transient oxygenation improvement in three patients with off-label intravenous administration of tPA (Alteplase). In another series, respiratory function improved in 3 out of 4 patients after the infusion of t-PA \[[@CR23]\]. Likewise, the effect of treatment with systemic tPA on COVID-19 associated ARDS has been estimated using a probabilistic model that predicts an improvement in pulmonary function and a reduction in mortality with the salvage use of tPA in these patients \[[@CR15]\].

This study has several limitations. It is known that ROTEM has limited sensitivity for the quantification of fibrinolytic activity and is not suitable for the detection of other haemostatic alterations such as platelet dysfunction or the endothelial role in coagulation \[[@CR20]\]. Additionally, the small sample size and the lack of medium-long term follow up precludes any predictive role of our findings in clinically-relevant hemostatic complications and outcomes, although this was not the aim of the study.

Nevertheless, our results highlight the potential pathophysiological pathways involved in hypoxemia in severe COVID19, which could allow more accurate targeted therapy.
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